Literature DB >> 9383230

Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.

T Parkkali1, M Stenvik, T Ruutu, T Hovi, L Volin, P Ruutu.   

Abstract

Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3) by a microneutralization assay prior to the first vaccination, at 6 months after BMT. The corresponding proportion for the late group patients was only 67% at 18 months. The antibody responses 1 month after each of the three IPV doses were similar in the two vaccination groups, except that four-fold responses occurred more frequently after the first dose to PV2 and PV3 in the late group. All patients had a protective antibody titre to all poliovirus serotypes 1 and 22 months after the third vaccine dose, except one patient in the early group who lacked antibodies to PV3 at 22 months. Acute GVHD accelerated the decrease of poliovirus antibody titres prior to vaccination but had no influence on vaccination response. Chronic GVHD neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations. A vaccination schedule consisting of three IPV doses was equally immunogenic when started at 6 or 18 months after allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9383230     DOI: 10.1038/sj.bmt.1700959

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Immunization for bone marrow transplant recipients.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2002-11

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors.

Authors:  Nancy Bunin; Trudy Small; Paul Szabolcs; K Scott Baker; Michael A Pulsipher; Troy Torgerson
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-17       Impact factor: 5.742

3.  Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

Authors:  A Ambati; L S V Boas; P Ljungman; L Testa; J F de Oliveira; M Aoun; V Colturato; M Maeurer; C M Machado
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

4.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.